Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) that has become one of veterinary oncology’s most widely used medications, prescribed far more often to fight cancer in dogs than to treat arthritis or everyday pain. Its best-studied use is against transitional cell carcinoma of the bladder, where it can shrink or stabilize tumors in a majority of treated dogs, but veterinarians also reach for it across several other cancer types. What makes piroxicam unusual among anti-inflammatory drugs is the strength of evidence for genuine antitumor activity, not just symptom relief, at a dose low enough to give daily for months.
How Piroxicam Works Against Cancer
Piroxicam belongs to the oxicam class of NSAIDs. Like other drugs in this family, it blocks cyclooxygenase (COX) enzymes, which are involved in producing prostaglandins that drive inflammation and pain. Many canine tumors overexpress COX-2, and that overexpression appears to help cancer cells survive, multiply, and recruit new blood vessels. Blocking COX-2 disrupts those processes.
Research in dogs with bladder cancer found that piroxicam shrank tumors in two-thirds of treated animals, and this tumor shrinkage was strongly linked to increased cancer-cell death through apoptosis, the body’s programmed cell-destruction pathway. The drug also lowered levels of basic fibroblast growth factor in urine, a marker of new blood-vessel formation that tumors rely on to grow.1PubMed. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer Lab studies on canine mammary carcinoma cells confirmed similar findings: piroxicam reduced cell viability and increased apoptosis at effective concentrations.2PubMed Central. The effects of piroxicam and deracoxib on canine mammary tumour cell line
The practical takeaway is that piroxicam does more than make a dog with cancer feel better by reducing inflammation around a tumor. It has direct effects on the cancer cells themselves, pushing them toward death and cutting off their blood supply. That dual action is why oncologists treat it as a low-grade chemotherapy agent rather than merely a comfort medication.
Bladder Cancer and Transitional Cell Carcinoma
Transitional cell carcinoma (TCC) of the urinary bladder is the cancer most closely associated with piroxicam therapy in dogs. TCC is the most common bladder tumor in dogs, and it tends to occur in breeds like Scottish Terriers, Shetland Sheepdogs, and Beagles. Surgery is often not possible because TCC typically grows in the trigone, the area where the ureters enter the bladder and the urethra exits, making complete removal extremely difficult without destroying urinary function.
An early clinical trial treating 34 dogs with TCC using piroxicam alone reported two complete remissions, four partial remissions, and stable disease in 18 dogs. Median survival was 181 days, with some dogs living well past two years.3PubMed. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder For a cancer that was historically considered nearly untreatable without aggressive surgery, those numbers represented a meaningful step forward. The complete remissions were especially striking because they came from an anti-inflammatory drug rather than traditional cytotoxic chemotherapy.
More recent work has examined piroxicam combined with standard chemotherapy agents. A randomized trial compared piroxicam plus mitoxantrone against piroxicam plus carboplatin as first-line treatment for dogs with urogenital TCC. After six weeks of treatment, neither combination produced complete responses, but partial remissions occurred in about 8 to 13 percent of dogs across the two groups, and stable disease was seen in over half to two-thirds of dogs in each arm. The progression-free intervals were similar between the two combinations, roughly 73 to 106 days.4PubMed Central. Randomized Phase III Trial of Piroxicam in Combination with Mitoxantrone or Carboplatin for First‐Line Treatment of Urogenital Tract Transitional Cell Carcinoma in Dogs The fact that piroxicam serves as the backbone in both arms tells you something about how central it has become to TCC management: it is treated less as an add-on and more as the foundation drug.
Other Cancers That Respond to Piroxicam
Bladder cancer gets the most attention, but piroxicam has shown activity against several other tumor types in dogs. The evidence for each varies in quality and size, but the overall pattern suggests the drug has broader anticancer properties beyond TCC.
Oral Squamous Cell Carcinoma
A study evaluating piroxicam alone for oral squamous cell carcinoma (SCC) in dogs reported one complete remission, two partial remissions, and stable disease in five additional dogs. The researchers noted that the response rate was comparable to what had been seen with conventional cytotoxic chemotherapy.5PubMed. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs When piroxicam was later combined with cisplatin for oral cancers, tumor remission occurred in five of nine dogs with SCC, though results were less impressive for oral malignant melanoma, where only two of eleven dogs responded.6PubMed. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs The difference between these two tumor types is worth noting: cancers that heavily express COX-2 seem to respond better, and melanoma does not always fit that profile.
Inflammatory Mammary Carcinoma
Inflammatory mammary carcinoma is one of the most aggressive cancers dogs can develop, and it historically carried a dismal prognosis. In a study of 12 dogs with the disease, all tumors showed strong COX-2 expression. Dogs treated with piroxicam achieved clinical improvement and disease stability, with a median progression-free survival of 183 days and a median overall survival of 185 days. By contrast, three dogs in the same study treated with doxorubicin-based chemotherapy had a median survival of just 7 days.7PubMed Central. Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment That difference is dramatic enough that piroxicam has become a standard consideration for this disease, though the study was small and the findings need that context.
Soft Tissue Sarcomas
When soft tissue sarcomas are surgically removed but the margins are not completely clean, the tumor may grow back. A study evaluating metronomic therapy, meaning low-dose continuous treatment, with cyclophosphamide and piroxicam after incomplete surgical removal found that the disease-free interval was significantly prolonged compared to untreated dogs. The combination delayed recurrence effectively enough that it is now a common recommendation after surgery leaves tumor cells behind.8Wiley Online Library. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas
Dosing and How the Drug Behaves in a Dog’s Body
The standard oncology dose for piroxicam in dogs is 0.3 mg per kilogram of body weight, given by mouth once daily. This dose was established through a phase I trial that tested escalating doses in 62 dogs with naturally occurring tumors. Dogs tolerated 0.3 mg/kg daily and up to 1 mg/kg every other day, but at 1.5 mg/kg every other day, all four dogs developed dose-limiting gastrointestinal ulceration. Subclinical damage to the kidneys, specifically renal papillary necrosis, was seen at the higher doses as well.9PubMed. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors
Piroxicam has a long half-life in dogs, around 33 to 40 hours depending on the study and the breed tested. In beagles given 0.3 mg/kg intravenously and orally, the elimination half-life was about 40 hours.10PubMed. Pharmacokinetics and pharmacodynamics of piroxicam in dogs Work in Nigerian indigenous dogs found a somewhat shorter half-life of roughly 34 hours.11Journal of King Saud University – Science. Effects of diminazene aceturate on flip-flop plasma pharmacokinetics of piroxicam in dogs That prolonged half-life is part of why once-daily dosing works: the drug stays at therapeutic levels in the bloodstream without needing multiple daily doses. It also means the drug accumulates over the first several days of treatment before reaching a steady state, which is relevant for monitoring side effects early on.
For metronomic protocols that combine piroxicam with low-dose cyclophosphamide, every-other-day dosing of piroxicam has been found to be better tolerated than daily dosing, with fewer gastrointestinal and bladder side effects.12Wiley Online Library. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas Your veterinarian may start with daily dosing and switch if problems arise, or begin with an every-other-day schedule from the outset.
Side Effects and Safety Concerns
The most common side effects of piroxicam in dogs involve the gastrointestinal tract. Vomiting, diarrhea, loss of appetite, and melena (dark, tarry stools indicating GI bleeding) are the issues owners should watch for. These occur because piroxicam inhibits COX-1 in addition to COX-2, and COX-1 helps maintain the protective mucus lining of the stomach and intestines. At the standard 0.3 mg/kg dose, GI side effects are manageable for most dogs, but they can become serious, especially with prolonged use or if the dog is also receiving corticosteroids or other NSAIDs.
Kidney damage is the second major concern. Prostaglandins produced by COX-1 help maintain blood flow to the kidneys. When piroxicam suppresses that, particularly in dogs that are dehydrated, elderly, or receiving nephrotoxic chemotherapy drugs, renal function can suffer. The phase I trial found subclinical renal papillary necrosis at doses above the standard range.13PubMed. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors When piroxicam is combined with cisplatin, the risk is especially pronounced because cisplatin itself is hard on the kidneys; the combination of direct tubular damage from cisplatin and impaired renal blood flow from COX-1 inhibition can be dangerous.14Molecular Cancer Therapeutics. Effects of the Cyclooxygenase Inhibitor, Piroxicam, in Combination with Chemotherapy on Tumor Response, Apoptosis, and Angiogenesis in a Canine Model of Human Invasive Urinary Bladder Cancer Most veterinary oncologists will run bloodwork, including kidney values and a urinalysis, before starting piroxicam and at regular intervals during treatment.
Sterile hemorrhagic cystitis, an inflammation of the bladder wall, can also occur, particularly with the piroxicam-cyclophosphamide metronomic combination. If your dog starts urinating more frequently, straining, or passing blood in the urine, the veterinarian needs to know immediately since those symptoms also overlap with the signs of the bladder cancer itself.
Drug Interactions to Know About
Piroxicam should never be given alongside corticosteroids like prednisone or dexamethasone. The combination dramatically increases the risk of GI ulceration and perforation. This can be a real-world problem because dogs with cancer are sometimes put on steroids for appetite stimulation or as part of a lymphoma protocol before a TCC diagnosis is made. If your dog has been on a steroid, a washout period is needed before starting piroxicam. Most veterinarians recommend waiting at least several days, and some prefer a longer gap.
Stacking piroxicam with other NSAIDs is equally dangerous. If a dog has been taking carprofen, meloxicam, or deracoxib for arthritis, switching to piroxicam for a cancer diagnosis requires a washout period as well. The idea that one NSAID is “fine” because the previous one was tolerated does not hold; the GI and renal risks compound when two prostaglandin-inhibiting drugs overlap in the body.
The interaction with cisplatin, as noted above, is worth special mention because cisplatin is a standard chemotherapy drug for several canine cancers. While some protocols do combine piroxicam with cisplatin, they require careful hydration protocols and close renal monitoring. Many oncologists now prefer carboplatin over cisplatin in part because it is less nephrotoxic and therefore safer alongside piroxicam.
Practical Considerations for Owners
Piroxicam typically comes in capsule form. Because the standard dose is weight-based and capsules come in fixed sizes (10 mg and 20 mg are common), getting an exact dose for a small dog can require compounding. Pharmacies can prepare custom capsules or liquid formulations, and some veterinary compounders have developed enteric-coated pellet formulations designed to release the drug past the stomach to reduce GI irritation.15Journal of King Saud University – Science. Effects of diminazene aceturate on flip-flop plasma pharmacokinetics of piroxicam in dogs If your veterinarian prescribes a compounded version, ask whether it has been formulated with GI protection in mind.
Giving piroxicam with food is standard practice to help buffer the stomach. Some owners also give a gastroprotectant such as omeprazole or sucralfate alongside piroxicam on the veterinarian’s recommendation. These can help reduce the risk of ulceration, though they do not eliminate it entirely.
Cost is one of piroxicam’s advantages. Compared with most injectable chemotherapy protocols, piroxicam is inexpensive. A month’s supply for a medium-sized dog can cost just a few dollars for the generic drug itself. The ongoing monitoring bloodwork adds to the overall expense, but the total treatment cost is substantially lower than IV chemotherapy regimens, which matters when families are weighing quality of life against budget constraints.
You should also know that piroxicam treatment for cancer is generally long-term, continuing as long as the dog tolerates it and the tumor remains controlled. There is no standard “course” of treatment with a defined endpoint the way there might be with, say, six rounds of IV chemotherapy. Dogs can stay on piroxicam for months or even years. The decision to stop usually comes when the tumor progresses despite treatment or when side effects become unmanageable.
When Piroxicam Is Not the Right Choice
Dogs with pre-existing kidney disease, active GI ulcers, or bleeding disorders are poor candidates. Dogs on anticoagulant therapy or high-dose aspirin present additional risks. Very young puppies and pregnant or nursing dogs should not receive the drug. If a dog has a tumor type that does not express COX-2 at high levels, the anticancer benefit of piroxicam may be limited, and a different treatment strategy could be more appropriate.
Some owners ask whether newer COX-2-selective NSAIDs like deracoxib or firocoxib could substitute for piroxicam with fewer side effects. Lab studies have shown that deracoxib does have antiproliferative effects on canine mammary carcinoma cells.16PubMed Central. The effects of piroxicam and deracoxib on canine mammary tumour cell line However, the clinical evidence base for these newer drugs in cancer treatment is much thinner than for piroxicam. Most published trials used piroxicam specifically, and veterinary oncologists tend to stick with it because the dosing, side-effect profile, and expected responses are well characterized from decades of clinical use. A newer NSAID might theoretically be gentler on the stomach, but without comparable cancer-specific data, the trade-off is not straightforward.
Piroxicam’s Role as a Model for Human Cancer Research
One reason piroxicam use in dogs has been studied so thoroughly is that canine TCC closely resembles human invasive bladder cancer at the molecular level. The same COX-2 overexpression, the same patterns of local invasion, and similar responses to COX inhibition make dogs with naturally occurring TCC a valuable research model for developing human cancer treatments. Studies of piroxicam’s effects on apoptosis and blood-vessel formation in canine TCC have directly informed human oncology trials investigating NSAIDs as adjunct cancer therapies.17Cancer Research. Effects of the Cyclooxygenase Inhibitor, Piroxicam, on Tumor Response, Apoptosis, and Angiogenesis in a Canine Model of Human Invasive Urinary Bladder Cancer
This cross-species connection has meant more research funding and attention devoted to canine TCC than it would otherwise receive, which in turn benefits the dogs. The extensive data on piroxicam’s anticancer mechanisms, its optimal dosing, its side-effect profile, and its interactions with chemotherapy agents all exist in part because of the interest in translating those findings to human patients. For dog owners navigating a cancer diagnosis, the silver lining is that piroxicam’s evidence base in veterinary oncology is unusually robust for a drug that costs so little and sits in a class most people associate only with pain relief.